PER percheron therapeutics limited

Ann: Phase IIb study of ATL1102 in DMD completes recruitment, page-58

  1. 872 Posts.
    lightbulb Created with Sketch. 846
    Hi George.

    I tried in my previous post to avoid sounding like I was criticising James, and I'm sorry if it came across in that way.
    I think the video discussed yesterday was very good, and he did a good job explaining everything.
    I did mention I wasn't restricting his skillset and this was a retail video and was targeted to retail investors.
    After watching the Cantor video it appears this solidifies that view, as the Cantor interview is targeted at a different audience than yesterdays video.
    Cantor was less lay and more specific and in-depth without consuming valuable time to explain the terminology and concepts that would be required for a less educated audience.
    In regard to the video it was great to listen to and hear further expansion on mechanisms and structures.
    It shows James medical knowledge aids James conceptual fluency and depth when discussing atl-1102.
    He shows passion in his understanding, and this is always a good thing.
    I think to go any deeper substantially would require George T or someone like Voight, but that would be more for published journals I think.

    I think your Premier League analogy is very apt George
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.9¢
Change
-0.001(10.0%)
Mkt cap ! $9.786M
Open High Low Value Volume
1.0¢ 1.0¢ 0.9¢ $94.66K 10.09M

Buyers (Bids)

No. Vol. Price($)
4 661860 0.9¢
 

Sellers (Offers)

Price($) Vol. No.
1.0¢ 1588275 6
View Market Depth
Last trade - 15.52pm 27/06/2025 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.